Tag: Securities and Exchange Commission

BELVIDERE, NJ, June 15, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today reminds shareholders to vote ahead of the Company’s Annual Meeting of Stockholders, which will be held on Wednesday, June 17, 2026, at 10:00 am Eastern Time. 

IRVINE, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (“CETY” or the “Company”) (Nasdaq: CETY), a clean energy technology company focused on sustainable energy and waste-to-value solutions, today announced the successful implementation of its advanced ORC component manufacturing initiative, which should substantially reduce production costs and improve supply chain efficiency for the Clean Cycle II (“CCII”) heat recovery systems.

PEKIN, Ill., June 15, 2026 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced that it has completed a sale transaction with a third-party corporate buyer for all of Alto Ingredients’ 2025 Section 45Z Clean Fuel Production Tax Credits generated from its low-carbon ethanol production.

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

FREMONT, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the appointment of Shanker Trivedi to its board of directors, effective immediately.

SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms